PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM Data

Core Viewpoint - PepGen Inc. is identified as a promising investment opportunity with a significant price target increase and strong performance in clinical studies [1][2]. Group 1: Company Performance - H.C. Wainwright has reaffirmed a 'Buy' rating on PepGen Inc. and raised the price target from $8.00 to $12.00, indicating a potential increase of nearly 135% [1]. - The company achieved a 53.7% mean splicing correction in its FREEDOM single-dose study for DM1 patients, marking the highest level reported in this patient group to date [1][2]. - PepGen Inc. delivered a return of 34.04%, significantly outperforming the market average of 13.10%, reflecting an impressive outperformance of nearly 21% [3]. Group 2: Company Overview - PepGen Inc., based in Boston, Massachusetts, is a clinical-stage biotechnology company focused on oligonucleotide therapeutics for severe neuromuscular and neurologic diseases [3]. - The company was founded in 2018 and offers several therapeutic candidates, including PGN-EDO51, PGN-EDODM1, and PGN-EDO53 [3].